Taysha Gene Therapies (TSHA) Q2 FY26 earnings call

Taysha Gene Therapies reported significant clinical and operational progress in Q2 FY26, completing dosing in both its pivotal REVEAL and ASPIRE trials for TSHA-102 in Rett syndrome. The company also strengthened its balance sheet with a $230 million financing, extending its cash runway into the second half of 2028. Payer research indicated strong support for TSHA-102's value proposition, driven by its transformative potential and convenient administration, reinforcing confidence in its commercial outlook despite an increase in net loss for the quarter.